Suppr超能文献

甲状腺髓样癌的外科治疗

Surgical management of medullary thyroid carcinoma.

作者信息

Konstantinidis Agathoklis, Stang Michael, Roman Sanziana A, Sosa Julie Ann

机构信息

Section of Endocrine Surgery, Department of Surgery, Duke University School of Medicine, DUMC 2945, Durham, NC, 27710, USA.

出版信息

Updates Surg. 2017 Jun;69(2):151-160. doi: 10.1007/s13304-017-0443-y. Epub 2017 Apr 13.

Abstract

Medullary thyroid cancer (MTC) is a malignant tumor of the parafollicular C cells of the thyroid and comprises only 1-2% of all thyroid cancer cases. Unlike most differentiated thyroid cancer, MTC is associated with a mean survival of 8.6 years and accounts for a disproportionate 8.6% of thyroid cancer deaths. Surgery is the mainstay of treatment for loco-regional disease and the only current means of cure for MTC. The relatively low incidence of MTC has made the comprehensive study of this disease difficult and most research to date has been based largely on single institution, retrospective, and/or non-randomized studies. Despite various professional organizations such as the American Thyroid Association establishing guidelines for the diagnosis and treatment of patients with MTC, there is still significant variation in actual practice patterns with regard to the extent of surgery, as well as the management of persistent or recurrent disease. The purpose of this review is to discuss the latest updates in the surgical treatment of MTC, as well as the management of locally advanced, recurrent, and metastatic disease based on the most recent data and expert consensus guidelines.

摘要

甲状腺髓样癌(MTC)是甲状腺滤泡旁C细胞的恶性肿瘤,仅占所有甲状腺癌病例的1%-2%。与大多数分化型甲状腺癌不同,MTC的平均生存期为8.6年,在甲状腺癌死亡病例中所占比例高达8.6%,极不相称。手术是局部区域疾病的主要治疗方法,也是目前治愈MTC的唯一手段。MTC相对较低的发病率使得对该疾病的全面研究较为困难,迄今为止,大多数研究主要基于单机构、回顾性和/或非随机研究。尽管诸如美国甲状腺协会等各种专业组织制定了MTC患者的诊断和治疗指南,但在手术范围以及持续性或复发性疾病的管理方面,实际的临床实践模式仍存在显著差异。本综述的目的是根据最新数据和专家共识指南,讨论MTC手术治疗的最新进展,以及局部晚期、复发和转移性疾病的管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验